8-Week Atopic Dermatitis (AD) Treatment Study

Procter & Gamble (P&G)

Status and phase: Completed; Phase 3

Conditions: Atopic Dermatitis Eczema

Treatments: Drug: Investigational OTC Cream; Drug: 0.05% Desonide; Other: Placebo Cream

Study type: Interventional

Funder types: Industry

Identifiers

NCT03386032

CSD2017168

Details and patient eligibility

About

This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).

Full description

This will be a 9-week, randomized, double blind, parallel comparison study consisting of a 1-week washout phase followed by an 8-week treatment phase. This study will be executed by one clinical research company utilizing two test sites and up to 62 subjects with moderate or severe atopic dermatitis, ages 12-65, will be enrolled. Subjects that are enrolled will be placed on one of three products (e.g. Sponsor's Experimental Cream Treatment, a basic moisturizer, or a positive control - Desonide) and will be required to use the assigned product twice a day for the duration of the 8-week treatment phase.

Enrollment: 65 patients

Sex: All

Ages: 12 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Is a generally healthy, male or female, 12-65 years old, inclusive;
• Diagnosis of moderate or greater Atopic Dermatitis as determined by SCORAD (SCORAD >=25);
• Is able to read and understand instructions in English.

Exclusion criteria

• Is currently participating or has participated in another interventional clinical study in the past 2 weeks;
• Currently or has been diagnosed or treated for cancer in the past 5 years;
• Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies);
• Has used systemic treatments that could affect AD within 30 days or 5 half- lives. (i.e. retinoids, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine and oral/injectable corticosteroids);
• Has a known hypersensitivity to any corticosteroid creams;
• Has been diagnosed with any allergies to Oat or derivatives;
• Has any active infections or has used antibiotics in the past 7 days;
• Has any physical attributes or skin conditions that might interfere with the clear visual or instrumental assessments.(i.e. cuts, sunburn, birth marks, tattoos, extensive scarring, excessive hair growth or acne);
• Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results;
• Has used any immunosuppressant drugs or immunotherapy within the past 30days or 5 half-lives;
• Is an employee of the sponsor company or clinical testing site;
• Is diabetic;
• Presents with the presence of an active or chronic allergic reaction as evidenced by an irregular white cell count determined by eosinophils > 0.3 X 109/L at Screening Visit;
• Is planning a trip to a sunny climate, to use tanning booths or use other UV sources throughout the course of this study;
• Has a history of hypersensitivity to any substance in investigational preparation or to Desonide;
• Has any clinically significant medical condition or laboratory abnormality that would, in the opinion of the Investigator, put the patient at undue risk or interfere with the interpretation of the study results;
• Is dependent on oral medication for any skin disease/condition or could not, in the opinion of the Investigator tolerate the restriction of discontinuing the medicine as required in this study;
• Is currently pregnant or lactating or planning to become pregnant in the next 6 months;
• Has other skin conditions that might interfere with AD diagnosis and/or evaluation (i.e. psoriasis current active viral, bacterial and fungal skin infections) as assessed by the Investigator;
• Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

65 participants in 3 patient groups

Investigational OTC Cream

Experimental group

Description:

Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.

Treatment:

Drug: Investigational OTC Cream

Placebo Cream

Sham Comparator group

Description:

Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.

Treatment:

Other: Placebo Cream

0.05% Desonide Cream

Active Comparator group

Description:

Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions. Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions.

Treatment:

Other: Placebo Cream

Drug: 0.05% Desonide